↑ 薬物リストへ　← 戻る

Cemdisiran    (DrugBank: Cemdisiran)

2 diseases
告示番号疾患名（ページ内リンク）臨床試験数
66IgA腎症4
109非典型溶血性尿毒症症候群6

66. IgA腎症　［臨床試験数：199，薬物数：214（DrugBank：57），標的遺伝子数：32，標的パスウェイ数：128］
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 199 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2018-002716-27-GB
(EUCTR)		11/06/201907/01/2019A Phase 2 Study of Cemdisiran in Adult Patients with IgA NephropathyA Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy - A Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy Immunoglobulin A nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: cemdisiran
Product Code: ALN-CC5
INN or Proposed INN: cemdisiran
Other descriptive name: CEMDISIRAN		Alnylam Pharmaceuticals IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Phase 2United States;France;Philippines;Taiwan;Canada;Spain;Malaysia;Singapore;United Kingdom;Sweden
2EUCTR2018-002716-27-SE
(EUCTR)		28/05/201906/02/2019A Phase 2 Study of Cemdisiran in Adult Patients with IgA NephropathyA Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy - A Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy Immunoglobulin A nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: cemdisiran
Product Code: ALN-CC5
INN or Proposed INN: cemdisiran
Other descriptive name: CEMDISIRAN		Alnylam Pharmaceuticals IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		30Phase 2United States;France;Philippines;Taiwan;Canada;Spain;Malaysia;Singapore;United Kingdom;Sweden
3NCT03841448
(ClinicalTrials.gov)		April 24, 201913/2/2019A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA NephropathyIgA Nephropathy (IgAN);Berger Disease;Glomerulonephritis, IgADrug: Placebo;Drug: CemdisiranAlnylam PharmaceuticalsNULLRecruiting18 Years65 YearsAll30Phase 2United States;Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom
4EUCTR2018-002716-27-ES
(EUCTR)		08/04/201912/04/2019A Phase 2 Study of Cemdisiran in Adult Patients with IgA NephropathyA Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy - A Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy Immunoglobulin A nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]Alnylam Pharmaceuticals IncNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		30Phase 2United States;Philippines;Taiwan;Spain;United Kingdom;France;Canada;Malaysia;Singapore;Australia;Germany;Sweden;Korea, Republic of

109. 非典型溶血性尿毒症症候群　［臨床試験数：95，薬物数：27（DrugBank：5），標的遺伝子数：2，標的パスウェイ数：9］
Searched query = "Atypical hemolytic uremic syndrome", "aHUS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 95 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03999840
(ClinicalTrials.gov)		January 202125/6/2019Eculizumab to Cemdisiran Switch in aHUSA Phase II, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Cemdisiran (ALN-CC5) Following Withdrawal of Chronic Eculizumab Therapy in Patients With Atypical HUS at High Risk of RecurrenceAtypical Hemolytic Uremic SyndromeDrug: cemdisiran;Drug: PlacebosMario Negri Institute for Pharmacological ResearchAlnylam PharmaceuticalsNot yet recruiting12 YearsN/AAll12Phase 2Italy
2EUCTR2017-001082-24-SE
(EUCTR)		20/11/201727/09/2017An international study at different study sites providing a drug called cemdisiran (ALN-CC5) to patients with Atypical Hemolytic Uremic Syndrome by a subcutaneous injectionA Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome Atypical Hemolytic Uremic Syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term: Hemolytic uremic syndrome;System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]		Alnylam Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes		24Phase 2Serbia;Estonia;Lithuania;India;Canada;Macedonia, the former Yugoslav Republic of;Romania;Albania;Georgia;Latvia;Moldova, Republic of;Sweden;Bosnia and Herzegovina
3NCT03303313
(ClinicalTrials.gov)		September 19, 201725/9/2017A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeA Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic SyndromeAtypical Hemolytic Uremic SyndromeDrug: CemdisiranAlnylam PharmaceuticalsNULLWithdrawn18 YearsN/AAll0Phase 2Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Serbia;Sweden
4EUCTR2017-001082-24-EE
(EUCTR)		15/09/201716/08/2017An international study at different study sites providing a drug called cemdisiran (ALN-CC5) to patients with Atypical Hemolytic Uremic Syndrome by a subcutaneous injectionA Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome Atypical Hemolytic Uremic Syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term: Hemolytic uremic syndrome;System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]		Alnylam Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes		24Phase 2Serbia;Estonia;Lithuania;India;Canada;Macedonia, the former Yugoslav Republic of;Romania;Albania;Georgia;Latvia;Moldova, Republic of;Sweden;Bosnia and Herzegovina
5EUCTR2017-001082-24-LT
(EUCTR)		23/08/201727/06/2017An international study at different study sites providing a drug called cemdisiran (ALN-CC5) to patients with Atypical Hemolytic Uremic Syndrome by a subcutaneous injectionA Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome Atypical Hemolytic Uremic Syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term: Hemolytic uremic syndrome;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]		Product Name: ALN-CC5
Product Code: ALN-CC5
INN or Proposed INN: cemdisiran		Alnylam Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes		24Phase 2Serbia;Estonia;Lithuania;India;Canada;Macedonia, the former Yugoslav Republic of;Romania;Albania;Georgia;Latvia;Moldova, Republic of;Sweden;Bosnia and Herzegovina
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6EUCTR2017-001082-24-LV
(EUCTR)		18/08/201720/06/2017An international study at different study sites providing a drug called cemdisiran (ALN-CC5) to patients with Atypical Hemolytic Uremic Syndrome by a subcutaneous injectionA Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome Atypical Hemolytic Uremic Syndrome
MedDRA version: 20.0;Level: LLT;Classification code 10019515;Term: Hemolytic uremic syndrome;System Organ Class: 100000004851 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]		Alnylam Pharmaceuticals, Inc.NULLNot Recruiting Female: yes
Male: yes		24Phase 2Serbia;Estonia;Macedonia, the former Yugoslav Republic of;Canada;Romania;Lithuania;Georgia;Albania;Latvia;Moldova, Republic of;Sweden;Bosnia and Herzegovina

先頭へ